

Notice of Annual General Meeting and Explanatory Memorandum

EPX Limited

ACN 645 144 314

Date: 27 November 2025

Time: 4.00pm (AEDT)

Place: Video Conference

Webcast: The Meeting will be held virtually via webcast and hosted on an online platform. Any security holder who wishes to attend the Meeting virtually may do so by accessing the following link:
<https://meetings.lumiconnect.com/300-343-048-230>

NOTICE OF 2025 ANNUAL GENERAL MEETING

Notice is given that the 2025 Annual General Meeting of
EPX Limited ACN 645 144 314 (the **Company**)
will be held via video conference
on 27 November 2025 at 4.00pm (AEDT)

BUSINESS OF THE MEETING

Shareholders are invited to consider the following items of business at the Annual General Meeting:

Ordinary Business

FINANCIAL AND RELATED REPORTS

Agenda Item	Financial and Related Reports
Description	To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditor's Reports in respect of the financial year ended 30 June 2025.

ADOPTION OF REMUNERATION REPORT (NON-BINDING VOTE)

Resolution 1	Adoption of Remuneration Report (non-binding vote)
Description	Shareholders are asked to adopt the Company's Remuneration Report. The Remuneration Report is set out in the 2025 Annual Report and is available from the Company's website (www.eptglobal.com/investor-centre). In accordance with section 250R of the Corporations Act, the vote on this Resolution will be advisory only and will not bind the Directors or the Company.
Resolution (Advisory)	To consider and, if thought fit, pass the following Resolution as an advisory resolution : <i>"THAT the Remuneration Report of the Company and its controlled entities for the year ended 30 June 2025 be adopted."</i>
Voting Exclusion	The Company will disregard any votes cast on this Resolution: <ul style="list-style-type: none">• by or on behalf of a member of Key Management Personnel (KMP) named in the Remuneration Report for the year ended 30 June 2025, or that KMP's Closely Related Party, regardless of the capacity in which the vote is cast; and• as a proxy by a member of the KMP at the date of the Meeting, or that KMP's Closely Related Party. However, the Company will not disregard a vote if it is cast as a proxy for a person who is entitled to vote on this Resolution: <ul style="list-style-type: none">• in accordance with the directions of how to vote on the Proxy Form; or• by the Chairman pursuant to an express authorisation on the Proxy Form.

ELECTION OF DIRECTOR

Resolution 2	Re-election of Mr Paul Oneile as Director
Resolution (Ordinary)	To consider and, if thought fit, pass the following Resolution as an ordinary resolution : <i>"THAT Mr Paul Oneile, who retires as a Director of the Company in accordance with ASX Listing Rule 14.4 and clause 47(c) of the Constitution and, being eligible, offers himself for re-election, be re-elected as a Director of the Company."</i>

RATIFICATION OF PLACEMENT SHARES

Resolution 3	Ratification of Placement Shares
Resolution (Ordinary)	To consider and, if thought fit, pass the following Resolution as an ordinary resolution : <i>"THAT, for the purpose of ASX Listing Rule 7.4 and all other purposes, Shareholders approve and ratify the issue of 90,909,091 Shares on 21 August 2025 on the terms and conditions set out in the Explanatory Memorandum accompanying this Notice."</i>
Voting Exclusion	The Company will disregard any votes cast in favour of this Resolution by or on behalf of any person who participated in the Placement of Shares or their Associates. However, this does not apply to a vote cast in favour of the Resolution by: <ul style="list-style-type: none">(a) A person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or(b) The Chairman as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chairman to vote on the Resolution as the Chairman decides; or(c) A holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:<ul style="list-style-type: none">o The beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and The holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

ISSUE OF PERFORMANCE RIGHTS TO DIRECTORS AND CEO

Resolution 4	Approval of Issue of Performance Rights to Directors and CEO
Resolution (Ordinary)	To consider and, if thought fit, pass the following resolution as an ordinary resolution: <i>"THAT, for the purposes of Listing Rule 10.14 and for all other purposes, shareholder approval is given for the Company to grant performance rights to the Directors of the Company, John Balassis, Elizabeth Aris, Paul Oneile and Victor Van Bommel, or their nominee(s), under the Employee Incentive Plan, pursuant to the terms set out in the Explanatory Memorandum accompanying this Notice."</i>
	The Company will disregard any votes cast in favour of these resolutions by:

Voting Exclusion	<p>(a) The Directors of the Company, being John Balassis, Elizabeth Aris, Paul Oneile and Victor Van Bommel and their nominee(s);</p> <p>(b) any associates of the persons named in sub-paragraph (a); and</p> <p>(c) as a proxy by a member of Key Management Personnel and a Closely Related Party of Key Management Personnel, where the proxy appointment does not specify the way the proxy is to vote.</p> <p>However, the Company will not disregard a vote if it is cast by:</p> <ul style="list-style-type: none"> ○ a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form that specify how the proxy is to vote on this resolution; or ○ the chair of the Meeting, as proxy for a person who is entitled to vote, in accordance with the directions of the proxy form that does not specify how the proxy is to vote on this resolution, but expressly authorises the chair to exercise the proxy even if the resolution is connected directly or indirectly with the remuneration of a member of Key Management Personnel. ○ a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: <ul style="list-style-type: none"> ▪ the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of the person excluded from voting, on the relevant resolution; and ▪ the holder votes on the relevant resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
-------------------------	--

APPOINTMENT OF AUDITOR

Resolution 5	Appointment of Auditor
Resolution (Special)	<p><i>To consider, and if thought fit, to pass with or without amendment, as a special resolution the following:</i></p> <p><i>“That, for the purposes of section 327B(1) of the Corporations Act 2001 and for all other purposes, BDO Audit Pty Limited, having been nominated by a Shareholder and consented in writing to act as Auditor of the Company, be appointed Auditor of the Company, effective immediately.”</i></p>

ADDITIONAL 10% PLACEMENT CAPACITY

Resolution 6	Additional 10% Placement Capacity
---------------------	--

<p>Resolution (Ordinary)</p>	<p>To consider and, if thought fit, pass the following resolution as an ordinary resolution:</p> <p>“THAT, for the purposes of Listing Rule 7.1A and for all other purposes, to approve the issue of additional equity securities up to 10% of the issued capital of the Company (at the time of issue), calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 over a 12 month period and on the terms and conditions set out in the Explanatory Memorandum accompanying this Notice.”</p>
<p>Voting Exclusion</p>	<p>The Company will disregard any votes cast in favour of these resolutions by:</p> <ul style="list-style-type: none"> (d) a person who is expected to participate in, or who will obtain a material benefit as a result of the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company); or (e) an associate of that person or those persons. <p>However, the Company will not disregard a vote if it is cast by:</p> <ul style="list-style-type: none"> ○ a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way or, ○ the chair of the Meeting, as proxy for a person who is entitled to vote, in accordance with the directions of the proxy form that does not specify how the proxy is to vote on this resolution, but expressly authorises the chair to exercise the proxy even if the resolution is connected directly or indirectly with the remuneration of a member of Key Management Personnel. ○ a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: <ul style="list-style-type: none"> ▪ the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of the person excluded from voting, on the relevant resolution; and ▪ the holder votes on the relevant resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

CONSOLIDATION OF CAPITAL OF THE COMPANY

Resolution 7	Consolidation of Capital of the Company
Resolution (Ordinary)	<p>To consider and, if thought fit, to pass the following resolution as an ordinary resolution:</p> <p><i>“That, for the purpose of Section 254H of the Corporations Act and the Company’s Constitution and for all other purposes, with effect from the date of this Resolution is passed (or such other date that is notified to the ASX by the Company) and otherwise on the terms and conditions set out in the Explanatory Memorandum, approval is given for the Company to consolidate its issued capital on the basis that:</i></p> <ul style="list-style-type: none"><i>• every 10 (ten) fully paid shares in the capital of the Company be consolidated into 1 (one) Share;</i><i>• the Options on issue be reorganised in accordance with Listing Rule 7.22; and</i><i>• the Performance Rights on issue be reorganised in accordance with Listing Rule 7.21, and</i><i>• where the consolidation results in a fraction of a Share, Option or Performance Right being held, the Company be authorised to round that fraction up to the nearest whole number.”</i>

Dated: 27 October 2025

By order of the Board of EPX Limited

Andrew Kabega
Company Secretary

QUESTIONS FROM SHAREHOLDERS

In order to provide an equal opportunity for all Shareholders to ask questions of the Board, we ask you to submit in writing any questions to the Company or to the Company's auditor, BDO Audit Pty Limited, in relation to the conduct of the external audit for the year ended 30 June 2025, or the content of its audit report. Please send your questions to:

The Company Secretary, **EPX Limited**, at BoardRoom Pty Limited, Level 8, 210 George Street, Sydney NSW 2000

E. company.secretary@boardroomlimited.com.au

Written questions must be received by no later than **5.00pm (AEDT) on 20 November 2025**.

Your questions should relate to matters that are relevant to the business of the Annual General Meeting, as outlined in this Notice of Meeting and Explanatory Memorandum.

In accordance with the *Corporations Act 2001* (Cth) and the Company's policy, a reasonable opportunity will also be provided to Shareholders attending the Annual General Meeting to ask questions about, or make comments upon, matters in relation to the Company including the Remuneration Report.

During the course of the Annual General Meeting, the Chairman will seek to address as many Shareholder questions as reasonably practicable, and where appropriate, will give a representative of the auditor the opportunity to answer written questions addressed to it. However, there may not be sufficient time to answer all questions at the Annual General Meeting. Please note that individual responses may not be sent to Shareholders.

VOTING INFORMATION

Voting by proxy

- (a) A Shareholder entitled to attend and vote at the Annual General Meeting may appoint one proxy or, if the Shareholder is entitled to cast 2 or more votes at the Meeting, 2 proxies, to attend and vote instead of the Shareholder.
- (b) Where 2 proxies are appointed to attend and vote at the Meeting, each proxy may be

appointed to represent a specified proportion or number of the Shareholder's voting rights at the Meeting.

- (c) A proxy need not be a Shareholder of the Company.
- (d) A proxy may be an individual or a body corporate. If a body corporate is appointed, the Proxy Form must indicate the full name of the body corporate and the full name or title of the individual representative of the body corporate for the Meeting.
- (e) A proxy form accompanies this Notice. If a Shareholder wishes to appoint more than 1 proxy, they may make a copy of the Proxy Form attached to this Notice. For the Proxy Form to be valid it must be received together with the power of attorney or other authority (if any) under which the form is signed, or a (notarially) **certified** copy of that power of authority by **4.00pm (AEDT) on 25 November 2025**:

Online	www.votingonline.com.au/epxagm2025
By post	Boardroom Pty Limited GPO Box 3993 Sydney NSW 2001
By personal delivery	BoardRoom Pty Limited Level 8 210 George Street Sydney NSW 2000
By facsimile	+61 9290 9655

Voting and other entitlements at the Annual General Meeting

A determination has been made by the Board of the Company under regulation 7.11.37 of the *Corporations Regulations* 2001 that Shares in the Company which are on issue at **7.00pm (AEDT) on 25 November 2025** will be taken to be held by the persons who held them at that time for the purposes of the Annual General Meeting (including determining voting entitlements at the Meeting).

Proxy voting by the Chairman

The *Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act* 2011 (Cth) imposes prohibitions on Key Management Personnel and their Closely Related Parties from voting their Shares (or voting

undirected proxies) on, amongst other things, remuneration matters.

However, the Chairman of a Meeting may vote an undirected proxy (i.e. a proxy that does not specify how it is to be voted), provided the Shareholder who has lodged the proxy has given an express voting direction to the Chairman to exercise the undirected proxy, even if the Resolution is connected with the remuneration of a member of Key Management Personnel. If you complete a Proxy Form that authorises the Chairman to vote on your behalf as proxy, and you do not mark any of the boxes so as to give him directions about how your vote should be cast, then you will be taken to have expressly authorised the Chairman to exercise your proxy on Resolution 1. In accordance with this express authority provided by you, the Chairman will vote in favour of Resolution 1. If you wish to appoint the Chairman as your proxy, and you wish to direct him how to vote, please tick the appropriate boxes on the form.

The Company's Chairman, Mr Paul Oneile, will chair the Meeting and intends to vote all available undirected proxies in favour of each item of business. If you appoint as your proxy any Director of the Company, except the Chairman, or any other Key Management Personnel or any of their Closely Related Parties and you do not direct your proxy how to vote on Resolution 1, he will not vote your proxy on that item of business.

Corporate Representative

Any corporate Shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that person with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company's representative. The authority can be mailed or faxed to the Company at least 24 hours before the Meeting. Alternatively, this document can be lodged at the registration desk on the day of the Meeting.

EXPLANATORY MEMORANDUM

TO NOTICE OF 2025 ANNUAL GENERAL MEETING

FINANCIAL AND RELATED REPORTS

Item 1	Financial and related reports
Explanation	<p>Section 317 of the Corporations Act requires the Company's financial report, directors' report and auditor's report for the financial year ended 30 June 2025 to be laid before the Company's 2025 Annual General Meeting. There is no requirement for a formal resolution on this item.</p> <p>The financial report contains the financial statements of the consolidated entity consisting of EPX Limited and its controlled entities.</p> <p>As permitted by the Corporations Act, a printed copy of the Company's 2025 Annual Report has been sent only to those Shareholders who have elected to receive a printed copy. A copy of the 2025 Annual Report is available from the Company's website (www.eptglobal.com/investor-centre).</p> <p>The Chairman will allow a reasonable opportunity at the Meeting for Shareholders to ask questions. Shareholders will also be given a reasonable opportunity at the Meeting to ask the Company's auditor, BDO Audit Pty Limited, questions about its audit report, the conduct of its audit of the Company's financial report for the year ended 30 June 2025, the preparation and content of its audit report, the accounting policies adopted by the Company in its preparation of the financial statements and the independence of BDO Audit Pty Limited in relation to the conduct of the audit.</p>

ADOPTION OF REMUNERATION REPORT (NON-BINDING RESOLUTION)

Resolution 1	Adoption of Remuneration Report (non-binding resolution)
Explanation	<p>Shareholders are asked to adopt the Company's Remuneration Report. The Remuneration Report is set out in the Company's 2025 Annual Report and is available from the Company's website (www.eptglobal.com/investor-centre).</p> <p>The Remuneration Report:</p> <ul style="list-style-type: none">describes the policies behind, and the structure of, the remuneration arrangements of the Company and the link between the remuneration of executives and the Company's performance;sets out the remuneration arrangements in place for each Director and for certain members of the senior management team; andexplains the differences between the basis for remunerating Non-Executive Directors and senior executives, including the Chief Executive Officer. <p>The vote on this item is advisory only and does not bind the Directors. The Board will take into account the discussion on this item and the outcome of the vote when considering the future remuneration policies and practices of the Company.</p>

Voting Consequences	<p>Under the Corporations Act, if at least 25% of the votes cast on a Remuneration Report Resolution are voted against the adoption of the Remuneration Report in two consecutive annual general meetings, the Company will be required to put to Shareholders a Resolution proposing the calling of an extraordinary general meeting to consider the appointment of Directors of the Company at the second annual general meeting (Spill Resolution).</p> <p>If more than 50% of Shareholders vote in favour of the Spill Resolution, the Company must convene the extraordinary general meeting (Spill Meeting) within 90 days of the second annual general meeting, at which all of the Directors (other than a managing director) of the Company, would need to stand for re-election.</p> <p>Following the Spill Meeting those persons whose election or re-election as Directors of the Company is approved by the Shareholders will be the Directors of the Company.</p> <p>At the Company’s previous annual general meeting, the votes cast against the Remuneration Report considered at that Annual General Meeting were less than 25%. Accordingly, the Spill Resolution is therefore not relevant for this Annual General Meeting.</p> <p>Shareholders should be aware that any undirected proxies given to the Chairman will be cast by the Chairman and counted in favour of Resolution 1, subject to compliance with the Corporations Act.</p>
Voting Exclusion	A voting exclusion statement applies to this Resolution, as set out in the Notice.
Board Recommendation	As the Resolution relates to matters including the remuneration of the Directors, the Board, as a matter of corporate governance and in accordance with the spirit of section 250R(4) Corporations Act, makes no recommendation regarding this Resolution.
Chairman’s available proxies	The Chairman intends to vote all available proxies in favour of this Resolution.

RE-ELECTION OF DIRECTORS

Resolutions 2	Re-election of Mr Paul Oneile as Director
Explanation	Clause 47(a) of the Constitution and ASX Listing Rule 14.4 requires that a Director must retire from office no later than the longer of the third annual general meeting of the Company or three years following the Director’s last election or appointment. In accordance with this, Mr Paul Oneile will retire and being eligible, seek re-election.
About Mr. Paul Oneile	Mr. Paul Oneile was appointed to the Board of the Company on 1 February 2024. Mr. Oneile is a highly experienced company director, who has held the positions of Chairman (Executive and Non-executive), Director, Managing Director and Chief Executive Officer of companies across a variety of industries, including roles within ASX-listed companies. Mr Oneile’s previous experience includes being the non-executive Deputy Chair of Thorn Group Limited, the non-executive Chair of Invigor Group Limited, non-executive Chair of A2B Australia Limited (formerly Cabcharge Australia Limited) and non-executive Chair of Intecq Limited (formerly eBet Limited) from 2012 until its acquisition by Tabcorp Holdings Limited in 2016. From 2003 to 2008, Mr. Oneile was CEO of Aristocrat Leisure Limited, where he oversaw

	significant business and cultural change which included, streamlining the supply chain operation and successfully oversaw the growth of the company's international operations.
Board Recommendation	The Board, with Mr. Oneile abstaining from voting on Resolution 2 recommends that Shareholders vote in favour of this Resolution.
Chairman's available proxies	The Chairman intends to vote all available proxies in favour of this Resolution.

RATIFICATION OF PLACEMENT SHARES

Resolution 3	Ratification of Placement Share Issue
Explanation	<p>On 21 August 2025, the Company issued 90,909,091 Shares to sophisticated and professional investors through a placement of shares (Placement). The purpose of the Placement was to (i) assist in advancing sales growth, (ii) assess further M&A opportunities, and (iii) invest in operational improvements in technology.</p> <p>Broadly speaking, and subject to a number of exceptions, ASX Listing Rule 7.1 limits the number of equity securities that a listed company can issue without the approval of its shareholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.</p> <p>The issue of Shares under this Resolution does not fit within any of these exceptions and, as they have not yet been approved by the Company's Shareholders, they effectively use part of the 15% limit in ASX Listing Rule 7.1, reducing the Company's capacity to issue further equity securities without Shareholder approval under ASX Listing Rule 7.1 for the 12-month period following the issue date.</p> <p>ASX Listing Rule 7.4 allows the shareholders of a listed company to approve an issue of equity securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under ASX Listing Rule 7.1 and so does not reduce the Company's capacity to issue further equity securities without Shareholder approval under that rule.</p> <p>The Company wishes to retain as much flexibility as possible to issue additional equity securities in the future without having to obtain Shareholder approval for such issues under ASX Listing Rule 7.1.</p> <p>The Directors believe that it is in the best interests of the Company to maintain its ability to issue securities under its 15% Placement Capacity, as this will enhance the Company's flexibility to finance its operations through raising equity capital, should the Directors consider it to be in the best interests of the Company to do so.</p> <p>To this end, this Resolution seeks Shareholder approval to the issue of Shares under and for the purposes of ASX Listing Rule 7.4.</p> <p>If this Resolution is passed, the Shares issued under the approved Resolution will be excluded in calculating the Company's 15% limit in ASX Listing Rule 7.1, effectively increasing the number of equity securities it can issue without Shareholder approval over the 12-month period following the date the securities were issued.</p> <p>If this Resolution is not passed, the Shares issued under the failed Resolution will be included in calculating the Company's 15% limit in ASX Listing Rule 7.1, effectively decreasing the number of equity securities it can issue without Shareholder approval over the 12-month period following the date the securities were issued.</p>

For personal use only

	<p>The Directors do not (save for as otherwise set out in this Notice) currently have any specific intention to make any further issue of securities without approval of Shareholders under ASX Listing Rule 7.1 in the next 12-months unless such issue falls under an exception to the 15% threshold in LR 7.2.</p> <p>The Directors believe that it is in the best interests of the Company to maintain its ability to issue securities under its Listing Rule 7.1 Placement Capacity, as this will enhance the Company's flexibility to finance its operations through raising equity capital, should the Directors consider it to be in the best interests of the Company to do so.</p>												
Specific information required by ASX Listing Rule 7.5	<p>For the purposes of ASX Listing Rule 7.5, the following information is provided to Shareholders in respect of this Resolution:</p> <table border="0"> <tr> <td>Number of securities issued</td> <td>A total of 90,909,091 Shares fully paid ordinary shares (Placement Shares) were issued under the Company's 15% placement capacity under ASX Listing Rule 7.1.</td> </tr> <tr> <td>Issue price per security</td> <td>\$0.022 per share</td> </tr> <tr> <td>Date on which the securities were issued</td> <td>The Placement Shares were issued on 21 August 2025 and an Appendix 2A was released to ASX on 21 August 2025.</td> </tr> <tr> <td>Name of allottees</td> <td>The Placement Shares were allocated to professional and sophisticated investors.</td> </tr> <tr> <td>Terms of securities</td> <td>Fully paid ordinary Shares that rank pari passu with those Shares already on issue.</td> </tr> <tr> <td>Use of funds</td> <td>The Funds raised have been, or proposed to be, used to (i) assist in advancing sales growth, (ii) assess further M&A opportunities, and (iii) invest in operational improvements in technology.</td> </tr> </table>	Number of securities issued	A total of 90,909,091 Shares fully paid ordinary shares (Placement Shares) were issued under the Company's 15% placement capacity under ASX Listing Rule 7.1.	Issue price per security	\$0.022 per share	Date on which the securities were issued	The Placement Shares were issued on 21 August 2025 and an Appendix 2A was released to ASX on 21 August 2025.	Name of allottees	The Placement Shares were allocated to professional and sophisticated investors.	Terms of securities	Fully paid ordinary Shares that rank pari passu with those Shares already on issue.	Use of funds	The Funds raised have been, or proposed to be, used to (i) assist in advancing sales growth, (ii) assess further M&A opportunities, and (iii) invest in operational improvements in technology.
Number of securities issued	A total of 90,909,091 Shares fully paid ordinary shares (Placement Shares) were issued under the Company's 15% placement capacity under ASX Listing Rule 7.1.												
Issue price per security	\$0.022 per share												
Date on which the securities were issued	The Placement Shares were issued on 21 August 2025 and an Appendix 2A was released to ASX on 21 August 2025.												
Name of allottees	The Placement Shares were allocated to professional and sophisticated investors.												
Terms of securities	Fully paid ordinary Shares that rank pari passu with those Shares already on issue.												
Use of funds	The Funds raised have been, or proposed to be, used to (i) assist in advancing sales growth, (ii) assess further M&A opportunities, and (iii) invest in operational improvements in technology.												
Board Recommendation	The Directors unanimously recommend that Shareholders vote in favour of this Resolution.												
Chairman's available proxies	The Chairman intends to vote all available proxies in favour of this Resolution.												

ISSUE OF PERFORMANCE RIGHTS TO DIRECTORS AND CEO

Resolution 4	Approval of Issue of Performance Rights to Directors and CEO
Description	<p>Resolution 4 seeks shareholder approval for the issue of:</p> <ol style="list-style-type: none"> 3,000,000 performance rights in the Company, to Mr. John Balassis, the Company's Executive Director and CEO, or his nominee(s) (Balassis Performance Rights); 1,000,000 performance rights in the Company, to Ms. Elizabeth Aris, an Independent Non- Executive Director of the Company, or her nominee(s) (Aris Performance Rights); and 1,000,000 performance rights in the Company, to Mr. Paul Oneile, Independent

	<p>Non- Executive Chair of the Company, or his nominee(s) (Oneile Performance Rights).</p> <p>4. 1,000,000 performance rights in the Company, to Mr. Victor Van Bommel, an Independent Non-Executive Director of the Company, or his nominee(s) (Van Bommel Performance Rights).</p>
<p>Shareholder Approval</p>	<p>Shareholder approval of the issue of the Balassis Performance Rights, Aris Performance Rights, Oneile Performance Rights and Van Bommel Performance Rights is sought for all purposes under the Corporations Act and the ASX Listing Rules, including for the following purposes:</p> <p>ASX Listing Rules</p> <p>In general, Listing Rule 10.14 provides that a company must not permit a director, an associate of a director, or a person whose relationship with the Company is, in ASX’s opinion, such that approval should be obtained, to acquire securities under an employee incentive scheme without shareholder approval.</p> <p>In accordance with the Listing Rules, shareholders are being asked under Resolution 4 to approve the grant of the Balassis Performance Rights, Aris Performance Rights, Oneile Performance Rights and Van Bommel Performance Rights (collectively the Performance Rights), and to the extent those Performance Rights vest, the underlying ordinary shares (Performance Shares).</p> <p>In considering the issue of performance rights to Paul Oneile, Elizabeth Aris and Victor Van Bommel, Non-Executive Directors, the Board acknowledges that the grant of performance rights to a Non-Executive Directors is contrary to the ASX Corporate Governance Principles and Recommendations which recommend that non-executive directors should normally be remunerated by way of fees, should not participate in schemes designed for remuneration of executives and should not receive options or performance rights. However, the Board considers the grant of the Oneile Performance Rights, Aris Performance Rights and Van Bommel Performance Rights constitutes cost effective consideration to Mr. Oneile, Mr. Van Bommel and Ms. Aris for their ongoing commitment and contribution to the Company and constitutes reasonable remuneration to the Directors in the circumstances of the Company and the Directors (including their responsibilities as Directors of the Company).</p> <p>Details of the remuneration for the Directors is shown below:</p>

	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments		Total
	Salary and fees	Cash bonus	Non-monetary	Super-annuation	Long service leave	Equity settled shares	Equity settled options	
2025	\$	\$	\$	\$	\$	\$	\$	\$
Non-Executive Directors:								
Paul Oneile	117,623	-	-	13,559	-	-	-	131,182
Elizabeth Aris	61,327	-	-	7,063	-	-	-	68,390
Victor van Bommel	65,004	-	-	-	-	-	-	65,004
Executive Director:								
John Balassis ¹	274,470	70,313	-	39,023	-	-	4,654	388,460
¹ The short-term incentive for John Balassis was delivered 50% in cash and 50% in shares. The share component was satisfied through the issue of ordinary shares on 9 July 2025 subsequent to year-end.								
	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments		Total
	Salary and fees	Cash commission bonus	Non-monetary	Super-annuation	Long service leave	Equity settled shares	Equity settled options	
2024	\$	\$	\$	\$	\$	\$	\$	\$
Non-Executive Directors:								
Victor van Bommel	48,753	-	-	-	-	16,251	12,403	77,407
Paul Oneile	49,210	-	-	5,458	-	-	-	54,668
Elizabeth Aris	17,443	-	-	1,939	-	-	-	19,382
Richard Doyle ³	20,739	-	-	2,281	-	-	-	23,020
Jonathan Sweeney ²	93,589	-	-	-	-	-	41,343	134,932
Executive								

Director:									
John Balassis	239,277	-	-	25,313	-	44,833	27,779	337,202	
Keith Gunaratne ¹	184,700	223,831	7,106	-	27,401	-	13,921	456,959	

¹ Keith Gunaratne is entitled to sales commission in line with the Sales Incentive Plan applicable to his role in force at the time. Sales commissions paid have been included in short-term cash bonuses and are 100% linked to contracted sales achieved by Keith Gunaratne.

Salary and fees for Keith Gunaratne were for the period 1 July 2023 to 29 November 2023 when he ceased to be a director and KMP.

The payments to Keith Gunaratne are translated against the average foreign currency rates during the year.

² Salary and fees for Jonathan Sweeney were for the period 1 July 2023 to 26 March 2024 when he resigned as a director.

³ Salary and fees for Richard Doyle were for the period 1 July 2023 to 29 November 2023.

Corporations Act

Chapter 2E of the Corporations Act requires that for a public company, or an entity that the public company controls, to give financial benefit to a related party of the public company, the public company or entity must:

- (a) Obtain the approval of the public company’s members in the manner set out in sections 217 to 227 of the Corporations Act; and
- (b) Give the benefit within 15 months following such approval,

Unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

The issue constitutes financial benefit and each of the proposed recipients is a related party of the Company by virtue of each being a Director.

As the Performance Rights are proposed to be issued to all of the Directors, the Directors are unable to form a quorum to consider whether one of the following exceptions set out in sections 210 to 216 of the Corporations Act applies to the issue. Accordingly, Shareholder approval for the issue is sought in accordance with Chapter 2E of the Corporations Act.

Terms of Performance Rights

All Performance Rights the subject of Resolution 4 has the same terms and vesting conditions, which include the following:

- The Performance Rights require EPX share price to exceed, continuously over any 30-day period commencing from grant date, a set share price hurdle. The share price hurdles are as follows (**Performance Hurdles**):
 - Tranche 1- 1 January 2026- to be issued at the higher of \$0.035cents or the 20-day VWAP just prior to 27 October 2025.
 - Tranche 2- 1 January 2027- \$0.045 cents
 - Tranche 3- 1 January 2028- \$0.06 cents
- The Performance Rights will expire 5 years from the grant date (**Expiry Date**).
- Performance Rights are allocated in equal tranches to each individual over a 3-year vesting period.
- Performance Rights cannot vest until the minimum vesting period has been satisfied, regardless of when the share price hurdles are achieved.
- Subject to the satisfaction of the Performance Hurdles in relation to each Director, the relevant Director will receive one share in the Company for each vested Performance Right. Any Performance Right which does not vest according to the vesting

	<p>requirements by the Expiry Date will lapse.</p> <ul style="list-style-type: none"> ▪ No cash consideration is payable for the issue of the Performance Rights, or on the issue of the underlying Performance Shares upon the vesting of the Performance Rights. ▪ The Performance Right participant is in continuous employment for the relevant vesting period year, in the role and with the responsibilities. ▪ The Performance Rights issued will not be transferable until vested and the shares are allocated. ▪ All Performance Rights vest on a takeover or change of control event. ▪ Any other factor/s which Board and/or the Remuneration Committee consider should be considered from time to time at the discretion of the Board and/or Remuneration Committee.
<p>Disclosures made for the purposes of Listing Rule 10.15</p>	<p>To enable shareholder approval to be effectively obtained under Listing Rule 10.14, the following information is provided in respect of the Balassis Performance Rights, Aris Performance Rights, Oneile Performance Rights and Van Bommel Performance Rights :</p> <ul style="list-style-type: none"> ▪ The Performance Rights will be issued to Mr. Paul Oneile, Mr. Victor Van Bommel, Mr. John Balassis and Ms. Elizabeth Aris. ▪ The maximum number of Performance Rights to be granted if Resolution 5 is approved is 6,000,000 Performance rights respectively. ▪ The issue price payable on the Performance Rights is nil. ▪ Once the Performance Hurdles are met, the Performance Rights vest and each of Mr. Balassis, Ms. Aris, Mr. Oneile and Mr. Van Bommel may call for the underlying Performance Shares to be issued to him. ▪ No persons referred to in ASX Listing Rule 10.14 has received securities under the Employee Incentive Plan since the last approval on 28 November 2024: ▪ The names of the persons referred to in Listing Rule 10.14 entitled to participate are Mr. Balassis, Ms. Aris, Mr. Oneile and Mr. Van Bommel. Voting exclusion statements apply to Resolution 4 and are included in the Notice. ▪ There is no loan proposed in relation to the proposed award of the Performance Rights to Mr. Balassis, Ms. Aris, Mr. Oneile and Mr. Van Bommel. ▪ Subject to approval, it is proposed that the Performance Rights be granted to Mr. Balassis, Ms. Aris, Mr. Oneile and Mr Van Bommel within 1 month of the Meeting, but in any event no later than 12 months after the date of the Meeting. ▪ Details of any Performance Rights issued under the Employee Incentive Plan will be published in each annual report of the Company relating to the period in which the Performance Rights were issued and, where applicable, it will be noted that approval for the issue of the Performance Rights was obtained under Listing Rule 10.14. ▪ Any additional persons covered by listing rule 10.14 who become entitled to participate in an issue of securities under the scheme after the resolution is approved and who were not named in the notice of meeting will not participate until approval is obtained under that rule. ▪ Summary of the material terms and conditions of the Employee Incentive Plan Rules is set out in Annexure A. <p>If Shareholder approval is not given in respect of Resolution 4 the Company may need to provide additional compensation to the Directors in cash. While the Board remains mindful of the need to minimise dilution to Shareholders, the Board considers that the issue of Performance Rights to the Directors is an appropriate and responsible cash-free method of aligning the interest of the Directors with that of Shareholders.</p>

Other Information	The Directors are not aware of any other information that is reasonably required by Shareholders to allow them to make a decision as to whether it is in the best interests of the Company to pass Resolution 4.
--------------------------	--

APPROVAL OF THE APPOINTMENT OF AUDITOR

Resolution 5	Appointment of Auditor
Explanation	<p>Having received ASIC consent, Grant Thornton Audit Pty Ltd resigned as auditor effective 20 May 2025. After receiving a consent to act, the Board moved to appoint, with effect from 28 April 2025, BDO Audit Pty Ltd pursuant to section 327C(1) of the Corporations Act.</p> <p>Pursuant to section 327C(2) of the Corporations Act, any auditor appointed under section 327C(1) of the Corporations Act holds office until the company's next annual general meeting. Accordingly, the Company would like to put the appointment of the Company's auditor before the members of the Company to formalise the appointment. The Company has received: (a) a nomination under section 328B of the Corporations Act from a member of the Company to appoint BDO Audit Pty Ltd as the Company's auditor; and (b) a consent to act as auditor of the Company duly executed by 22 April 2025. A copy of the nomination is attached to this Notice at Annexure B. If Resolution 5 is passed, BDO Audit Pty Ltd will continue in its position as the Company's auditor.</p>
Board Recommendation	The Directors of the Company recommend that shareholders vote in favour of this resolution.
Chairman's available proxies	The Chairman of the Meeting intends to vote all available proxies in favour of this Resolution.

ADDITIONAL 10% CAPACITY

Resolution 6	Additional 10% capacity
Explanation	ASX Listing Rule 7.1A provides that an eligible entity (as defined below) may seek Shareholder approval at its annual general meeting to allow it to issue equity securities up to 10% of its issued capital at the time of the issue over a period up to 12 months after the annual general meeting (10% Placement Capacity). If Shareholders approve Resolution 6,

the number of equity securities the Company may issue under the 10% Placement Capacity will be determined in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 (as set out below).

The effect of Resolution 6 will be to allow the Directors to issue equity securities up to 10% of the Company's fully paid ordinary securities on issue at the time of the issue under the 10% Placement Capacity during the period up to 12 months after the Meeting, without subsequent Shareholder approval and without using the Company's 15% annual placement capacity granted under ASX Listing Rule 7.1. Resolution 6 is a special resolution and therefore requires approval of 75% of the votes cast by Shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative).

Under Listing Rule 7.1A, however, an eligible entity can seek approval from its members, by way of a special resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% to 25%.

When the Company issues Equity Securities pursuant to the 10% Placement Capacity, the Company must:

- a) State in its announcement of the proposed issue of Equity Securities under ASX Listing Rule 3.10.3 or in its application for quotation of the Equity Securities under ASX Listing Rule 2.7 that the Equity Securities are being issued under ASX Listing Rule 7.1A; and
- b) Give to ASX immediately after the issue a list of names of the persons to whom the Company issued the Equity Securities issued and the number of Equity Securities issued to each (not for release to the market).

The Directors of the Company believe that Resolution 6 is in the best interests of the Company and unanimously recommend that Shareholders vote in favour of this Resolution.

Resolution 6 is a special resolution. Accordingly, at least 75% of votes cast by Shareholders present and eligible to vote at the Meeting must be in favour of Resolution 6 for it to be passed.

ASX Listing Rule 7.1A

ASX Listing Rule 7.1A enables an Eligible Entity to seek shareholder approval at its annual general meeting to issue equity securities in addition to those under the Eligible Entity's 15% annual placement capacity.

An Eligible Entity is one that, as at the date of the relevant annual general meeting:

- a) is not included in the S&P/ASX 300 Index; and
- b) has a maximum market capitalisation (excluding restricted securities and securities quoted on a deferred settlement basis) of \$300 million.

The Company is an Eligible Entity as it is not included in the S&P/ASX 300 Index and has a current market capitalization of approximately \$29.27 million as at 30 September 2025.

Any equity securities issued must be in the same class as an existing class of quoted equity securities issued for cash consideration per security per LR 7.1A.3.

The Company currently has the following classes of security, being:

- 750,586,191 quoted fully paid ordinary shares (ASX Code: EPX);

The exact number of equity securities that the Company may issue under an approval under ASX Listing Rule 7.1A will be calculated according to the following formula:

$$(A \times D) - E$$

A = the number of fully paid +ordinary securities on issue at the commencement of the relevant period,

- plus the number of fully paid ordinary securities issued in the relevant period under an exception in rule 7.2 other than exception 9, 16 or 17,
- plus the number of fully paid ordinary securities issued in the relevant period on the conversion of convertible securities within rule 7.2 exception 9 where:
 - the convertible securities were issued or agreed to be issued before the commencement of the relevant period; or
 - the issue of, or agreement to issue, the convertible securities was approved, or taken under these rules to have been approved, under rule 7.1 or rule 7.4,
- plus the number of fully paid ordinary securities issued in the relevant period under an agreement to issue securities within rule 7.2 exception 16 where:
 - the agreement was entered into before the commencement of the relevant period; or
 - the agreement or issue was approved, or taken under these rules to have been approved, under rule 7.1 or rule 7.4,
- plus the number of any other fully paid ordinary securities issued in the relevant period with approval under rule 7.1 or rule 7.4,

Note: This may include fully paid ordinary securities issued in the relevant period under an agreement to issue securities within rule 7.2 exception 17 where the issue is subsequently approved under rule 7.1.

- plus the number of partly paid ordinary securities that became fully paid in the relevant period,
- less the number of fully paid ordinary securities cancelled in the relevant period;

D is 10%.

	<p>E is the number of equity securities issued or agreed to be issued under ASX Listing Rule 7.1A.2 in the relevant period where the issue or agreement has not been approved by the holders of ordinary securities under ASX Listing Rule 7.4.</p>
<p>Specific Information required by ASX Listing Rule 7.1A</p>	<p>Pursuant to and in accordance with ASX Listing Rule 7.3A, the information below is provided in relation to this Resolution 6:</p> <p>Minimum Price</p> <p>The minimum price at which the equity securities may be issued is 75% of the volume weighted average price of equity securities in that class, calculated over the 15 ASX trading days on which trades in that class were recorded immediately before:</p> <ul style="list-style-type: none"> (a) the date on which the price at which the equity securities are to be issued is agreed; or (b) if the equity securities are not issued within 10 trading days of the date in Section 4.3(a)(i), the date on which the equity securities are issued. <p>Date of Issue</p> <p>The equity securities may be issued under the 10% Placement Capacity commencing on the date of the Meeting and expiring on the first to occur of the following:</p> <ul style="list-style-type: none"> (a) 12 months after the date of this Meeting at which the approval is obtained; (b) The time and date of the company’s next AGM; and (c) the date of approval by Shareholders of any transaction under ASX Listing Rules 11.1.2 (a significant change to the nature or scale of the Company’s activities) or 11.2 (disposal of the Company’s main undertaking). <p>Risk of economic and voting dilution</p> <p>Shareholders should be aware there is a risk of economic and voting dilution that may result from an issue of equity securities under the 10% Placement Capacity, including the risk that:</p> <ul style="list-style-type: none"> • the market price for equity securities in that class may be significantly lower on the issue date than on the date of the Meeting where approval is being sought; and • the equity securities may be issued at a price that is at a discount to the market price for those equity securities on the date of issue. <p>Any issue of equity securities under the 10% Placement Capacity will dilute the interests of Shareholders who do not receive any Shares under the issue.</p> <p>If Resolution 6 is approved by Shareholders and the Company issues the maximum number of equity securities available under the 10% Placement Capacity, the economic and voting dilution of existing Shares would be as shown in the table below.</p>

The table below shows the dilution of existing Shareholders calculated in accordance with the formula outlined in ASX Listing Rule 7.1A(2), on the basis of the current market price of Shares and the current number of equity securities on issue as at the date of this Notice.

The table also shows the voting dilution impact where the number of Shares on issue (variable A in the formula) changes and the economic dilution where there are changes in the issue price of Shares issued under the 10% Placement Capacity.

Variable A in Listing Rule 7.1.A.2		\$ 0.0195 50% decrease in issue price	\$ 0.0390 Issue Price	\$ 0.0780 100% increase in issue price
Current				
Variable A	10% Voting Dilution	75,058,619	75,058,619	75,058,619
750,586,191	Funds Raised	\$ 1,463,643	\$ 2,927,286	\$ 5,854,572
50% increase in Current				
Variable A	10% Voting Dilution	112,587,929	112,587,929	112,587,929
1,125,879,287	Funds Raised	\$ 2,195,465	\$ 4,390,929	\$ 8,781,858
100% increase in current				
Variable A	10% Voting Dilution	150,117,238	150,117,238	150,117,238
1,501,172,382	Funds Raised	\$ 2,927,286	\$ 5,854,572	\$11,709,145

*Subject to the approval of resolution 7, the number of Shares on issue (variable A in the formula) will decrease as a result of the proposed share consolidation.

Notes:

¹ The table has been prepared on the following assumptions:

- (a) The Company issues the maximum number of shares available under ASX Listing Rule 7.1A;
- (b) The table shows only the effect of shares issued under ASX Listing Rule 7.1A and does not factor in the Company's ability to issue up to 15% of its issued capital under ASX Listing Rule 7.1;
- (c) The current issue price is \$0.038, being the closing price of the Shares on ASX on 30 September 2025.
- (d) The current number of securities on issue is the Shares on issue as at 30 September 2025, being 750,586,191.

The table shows:

- two examples where Variable "A" has increased, by 50% and 100%. Variable "A" is based on the number of Shares the Company has on issue. The number of

Shares on issue may increase as a result of issues of Shares that do not require approval (for example, a pro rata entitlements issue) or future specific placements under ASX Listing Rule 7.1 that are approved at a future Shareholders' meeting; and

- two examples of where the issue price of shares decreased by 50% and increased by 100% as against the current market price.

Period for which the approval will be valid

If Shareholder approval is granted for Resolution 6, then that approval will expire on the earlier of:

- 27 November 2026, being 12 months from the date of the Meeting;
- the time and date of the Company's next Annual General Meeting; or
- the date Shareholder approval is granted to a transaction under ASX Listing Rule 11.1.2 (proposed change to nature and scale of activities) or ASX Listing Rule 11.2 (change involving main undertaking).

The approval under ASX Listing Rule 7.1A will cease to be valid in the event that Shareholders approve a transaction under ASX Listing Rule 11.1.2 or 11.2.

Purpose of Issue under 10% Placement Capacity

The Company may issue equity securities under the 10% Placement Capacity for various purposes including general working capital purposes and raise funds to further develop the Company's product offering as required.

The Company will comply with the disclosure obligations under Listing Rules 7.1A.4 and 3.10.3 upon issue of any Equity Securities.

Allocation under the 10% Placement Capacity

The allottees of the equity securities to be issued under the 10% Placement Capacity have not yet been determined. However, the allottees of equity securities could consist of current Shareholders or new investors (or both), none of whom will be related parties of the Company.

The Company will determine the allottees at the time of the issue under the 10% Placement Capacity, having regard to the following factors:

- the purpose of the issue;
- alternative methods for raising funds available to the Company at that time, including, but not limited to, an entitlement issue or other offer where existing Shareholders may participate;
- the effect of the issue of the equity securities on the control of the Company;
- the circumstances of the Company, including, but not limited to, the financial position and solvency of the Company;
- prevailing market conditions; and
- advice from corporate, financial, and broking advisers (if applicable).

	<p>Securities issued or agreed to be issued under rule 7.1A.2 in the 12 months preceding the date of Meeting</p> <p>The Company issued nil Shares under ASX Listing Rule 7.1A.2 over the 12 months preceding the date of the Meeting.</p> <p>Compliance with ASX Listing Rules 7.1A.4 and 3.10.3</p> <p>When the Company issues equity securities pursuant to the 10% Placement Capacity, it will give ASX:</p> <ul style="list-style-type: none"> a) a list of the names of the persons to whom the Company issues the equity securities and the number of equity securities allotted to each (not for release to the market), in accordance with ASX Listing Rule 7.1A.4; and b) the information required by ASX Listing Rule 3.10.3 for release to the market. <p>(g) At the date of the Notice of Meeting, the Company has not invited and has not determined to invite any particular existing Shareholder or an identifiable class of existing Shareholder to participate in an offer under ASX Listing Rule 7.1A. Accordingly, no existing Shareholder will be excluded from voting on this Resolution.</p>
<p>Board Recommendation</p>	<p>The Directors unanimously recommend that shareholders vote in favour of this resolution.</p>
<p>Chairman's available proxies</p>	<p>The Chairman intends to vote all available proxies in favour of this Resolution.</p>

CONSOLIDATION OF CAPITAL OF THE COMPANY

<p>Resolution 7</p>	<p>Consolidation of Capital of the Company</p>
<p>Explanation</p>	<p>Resolution 7 seeks Shareholder approval for the Company to consolidate its issued share capital through the conversion of every 10 (ten) Shares into 1 (one) Share (Consolidation). Similarly, the Options and Performance Rights on issue will be consolidated on the same basis in accordance with ASX Listing Rules 7.21 and 7.22.1.</p> <p>Pursuant to Section 254H(1) of the Corporations Act, the Company may convert all or any of its Shares into a larger or smaller number of Shares by ordinary resolution passed at a general meeting.</p>

<p>Purpose of the Resolution</p>	<p>The reasons for the proposal are as follows:</p> <ul style="list-style-type: none"> ▪ The Share Consolidation will result in a more appropriate and effective capital structure for the Company and a Share price more appealing to a wider range of investors globally. ▪ The Share Consolidation is appropriate as the Company moves to bring the Company's capital structure more in line with its peers on the ASX.
<p>Effect of the Share Consolidation</p>	<p>ASX Listing Rule 7.20 provides that if an entity proposes to reorganise its capital, it must advise shareholders of certain matters which are set out below.</p> <p>(a) Shares</p> <p>The Company currently has 750,586,191 Shares on issue. If this Resolution is approved, every 10 Shares on issue will be consolidated into 1 Share (subject to rounding). Following the Consolidation, the number Shares on issue would be reduced from 750,586,191 to approximately 75,058,619 (subject to rounding), making the number of Shares on issue more manageable and at an expected share-price that investment parties would feel more comfortable with.</p> <p>Other than minor changes as a result of rounding, the Consolidation will not change the proportionate interest that each Shareholder holds in the Company. As the Consolidation applies equally to all Shareholders, individual Shareholdings will be reduced in the same ratio as the total number of Shares (subject to rounding). In the absence of market movements or other impacts, the Consolidation will theoretically have no effect (other than minor changes as a result of rounding) on the aggregate value of each Shareholder's holding or the Company's market capitalisation.</p> <p>The Consolidation will not result in any change to the substantive rights and obligations of existing Shareholders.</p> <p>(b) Options</p> <p>As at the date of this Notice, the Company has 16,466,555 Options on issue. If the Consolidation is approved, the Options will be reorganised in accordance with the terms and conditions of the Options and ASX Listing Rule 7.22.1 (as applicable) on the basis that the number of Options will be consolidated in the same 10 (ten) for 1 (one) ratio as the Consolidation and the exercise price will be amended in inverse proportion to that ratio.</p> <p>If the Consolidation is approved, the total number of Options on issue will reduce from 16,466,555 to approximately 1,646,655 (subject to rounding). The expiry dates for each batch of Options will remain the same. The exercise price for each Option following the Options consolidation will be 10 times their exercise price prior to the Consolidation.</p> <p>For example, a holding of 100,000 Options with an exercise price of \$0.05 each prior to the Consolidation will result in a holding of 10,000 Options with an exercise price of \$0.50 each after the Consolidation.</p> <p>Other than the number of Options and the exercise price, the Consolidation will not result in any change to the terms of the Options or the substantive rights and obligations of existing holders of Options.</p> <p>(c) Performance Rights</p>

	<p>ASX Listing Rule 7.21 provides that an entity with convertible securities on issue (such as performance rights) may only reorganise its capital if the number of performance rights, or the conversion price, or both is reorganised so that the holder of the convertible securities will not receive a benefit that holders of ordinary shares do not receive.</p> <p>As at the date of this Notice, the Company has 12,500,000 Performance Rights on issue. If the Consolidation is approved, then the Performance Rights will also be reorganised in accordance with the terms and conditions of the Performance Rights and Listing Rule 7.21 on the basis that the number of Performance Rights will be consolidated in the same 10 (ten) for 1 (one) ratio as the Consolidation.</p> <p>If the Consolidation is approved, the total number of Performance Rights on issue will reduce from 12,500,000 to approximately 1,250,000 (subject to rounding).</p> <p>Other than the number of Performance Rights and, where applicable, any share price or conversion price vesting conditions, the Consolidation will not result in any change to the terms of the Performance Rights or the substantive rights and obligations of the existing holders of Performance Rights</p>
<p>Fractional Entitlements</p>	<p>Where the Consolidation results in an entitlement to a fraction of a Share or Option or Performance Right (as applicable), that fraction will be rounded up to the nearest whole number of Shares or Options or Performance Rights.</p>
<p>Holding Statements</p>	<p>From the effective date of the Share Consolidation, all existing holding statements will cease to have any effect, except as evidence of entitlement to a certain number of securities on a post- consolidation basis. New holding statements will be issued to security holders who should check their holdings after the Share Consolidation</p>
<p>Tax Implications of Share Consolidation</p>	<p>The Share Consolidation should not result in a capital gains tax (CGT) event for Australian tax residents. The cost base of the Shares held after the Share Consolidation will be the sum of the cost bases of the original Shares pre- consolidation. The acquisition date of Shares held after the Share Consolidation will be the same as the date on which the original Shares were acquired. These statements do not consider the tax implications in respect of Shares or securities held on revenue account, as trading stock, by non-resident Shareholders or under the Share Rights Plan or Executives’ Options Plan. Shareholders should consider their own circumstances and seek their own professional advice in relation to their tax position. Neither the Company nor any of its officers or employees assumes any liability or responsibility for advising Shareholders or securities holders about the tax consequences of the proposed Share Consolidation.</p>

Indicative Timetable	The proposed Share Consolidation, if approved by Shareholders, will take effect pursuant to the following timetable (subject to change) in accordance with Appendix 7A (section 8) of the ASX Listing Rules:																		
	<table border="1"> <thead> <tr> <th>Event</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>Notice of Meeting despatched along with ASX Appendix 3A.3 and announcement of Consolidation (including the effective date)</td> <td>Monday, 27 October 2025</td> </tr> <tr> <td>Shareholder approval at Annual General Meeting. Company notifies ASX that the consolidation is approved. Effective Date of Consolidation (Day 0)</td> <td>Thursday, 27 November 2025</td> </tr> <tr> <td>Last day for trading pre-Consolidation securities</td> <td>Friday, 28 November 2025</td> </tr> <tr> <td>Trading in reorganized securities commences on a deferred settlement basis (Day 2)</td> <td>Monday, 1 December 2025</td> </tr> <tr> <td>Record Date for Consolidation. Last day for Company to register transfers on a pre-Consolidation basis (Day 3)</td> <td>Tuesday, 2 December 2025</td> </tr> <tr> <td>Registration of securities on a post-Consolidation basis. First day to send new Holding Statements (Day 4)</td> <td>Wednesday, 3 December 2025</td> </tr> <tr> <td>Deferred Settlement trading ends. Last day to update register and send notice to all shareholders (and notification to ASX that this has occurred) (Day 8)</td> <td>Tuesday, 9 December 2025</td> </tr> <tr> <td>Normal trading in reorganised securities commences (Day 9)</td> <td>Wednesday, 10 December 2025</td> </tr> </tbody> </table>	Event	Date	Notice of Meeting despatched along with ASX Appendix 3A.3 and announcement of Consolidation (including the effective date)	Monday, 27 October 2025	Shareholder approval at Annual General Meeting. Company notifies ASX that the consolidation is approved. Effective Date of Consolidation (Day 0)	Thursday, 27 November 2025	Last day for trading pre-Consolidation securities	Friday, 28 November 2025	Trading in reorganized securities commences on a deferred settlement basis (Day 2)	Monday, 1 December 2025	Record Date for Consolidation. Last day for Company to register transfers on a pre-Consolidation basis (Day 3)	Tuesday, 2 December 2025	Registration of securities on a post-Consolidation basis. First day to send new Holding Statements (Day 4)	Wednesday, 3 December 2025	Deferred Settlement trading ends. Last day to update register and send notice to all shareholders (and notification to ASX that this has occurred) (Day 8)	Tuesday, 9 December 2025	Normal trading in reorganised securities commences (Day 9)	Wednesday, 10 December 2025
	Event	Date																	
	Notice of Meeting despatched along with ASX Appendix 3A.3 and announcement of Consolidation (including the effective date)	Monday, 27 October 2025																	
	Shareholder approval at Annual General Meeting. Company notifies ASX that the consolidation is approved. Effective Date of Consolidation (Day 0)	Thursday, 27 November 2025																	
	Last day for trading pre-Consolidation securities	Friday, 28 November 2025																	
	Trading in reorganized securities commences on a deferred settlement basis (Day 2)	Monday, 1 December 2025																	
	Record Date for Consolidation. Last day for Company to register transfers on a pre-Consolidation basis (Day 3)	Tuesday, 2 December 2025																	
	Registration of securities on a post-Consolidation basis. First day to send new Holding Statements (Day 4)	Wednesday, 3 December 2025																	
	Deferred Settlement trading ends. Last day to update register and send notice to all shareholders (and notification to ASX that this has occurred) (Day 8)	Tuesday, 9 December 2025																	
Normal trading in reorganised securities commences (Day 9)	Wednesday, 10 December 2025																		
The Directors reserve the right to change the above indicative timetable without requiring any disclosure to Shareholders subject to the ASX Listing Rules and all applicable law. The above timetable is indicative only.																			
Unless indicated otherwise, any reference to the number of securities in resolutions 3, 4 and 6 (inclusive) of this Notice and the Explanatory Memorandum is a reference to the number of securities prior to the passing of this resolution 7.																			
If this resolution is passed, any securities issued or approved in resolutions 3, 4 and 6 (inclusive) of this Notice will be consolidated or reorganised (as applicable) on the same basis outlined under the heading "Effect of the Consolidation" above.																			
Board Recommendation	The Directors unanimously recommend that Shareholders vote in favour of this Resolution.																		
Chairman's available proxies	The Chairman intends to vote all available proxies in favour of this Resolution.																		

DEFINITIONS

ASX	Means ASX Limited ACN 008 624 691.
ASX Listing Rules	Means the listing rules of the ASX.
Annual General Meeting	Means the annual general meeting of the Company for 2025 to which the Notice relates.
Chairman	Means the chairman of the Annual General Meeting.
Company or EPX Limited	Means EPX Limited ACN 645 144 314.
Constitution	Means the Company's constitution.
Corporations Act	Means the <i>Corporations Act 2001</i> (Cth).
Closely Related Party (of a member of KMP of an entity)	Has the definition given to it by section 9 of the Corporations Act, and means: <ul style="list-style-type: none"> a) a spouse or child of the member; or b) a child of the member's spouse; or c) a dependant of the member or of the member's spouse; or d) anyone else who is one of the member's family and may be expected to influence the member, or be influenced by the member, in the member's dealings with the entity; or e) a company the member controls; or f) a person prescribed by the regulations for the purposes of this definition.
Director	Means a director of the board of EPX Limited.
Explanatory Memorandum	Means this explanatory memorandum accompanying and forming part of the Notice.
Key Management Personnel or KMP	Means those people described as Key Management Personnel in the Remuneration Report and includes all directors.
Meeting	Means the Annual General Meeting of the Company for 2025 to which the Notice relates.
Notice	Means this notice of meeting of the Company, including the accompanying Explanatory Memorandum.
Proxy Form	Means the proxy form that is enclosed with and forms part of this Notice.
Remuneration Report	Means the remuneration report set out in the Directors' Report section of the Company's annual financial report for the year ended 30 June 2025.

Resolution	Means a Resolution set out in this Notice.
Share	Means a fully paid ordinary share in the capital of the Company.
Shareholder	Means a holder of at least one Share in the Company.

Annexure A: Employee Incentive Plan- Summary of Plan Rules

Employee Incentive Plan EPX has established an employee incentive plan (Employee Incentive Plan) which provides the framework under which individual grants of employee incentives outside the STIP are proposed to operate. The key terms of the Employee Incentive Plan are outlined below

TOPIC	SUMMARY
Administration	The Employee Incentive Plan will be administered by the Board.
Eligibility	Participation in the Plan is by invitation (Invitation). Eligible participants are full-time or part-time employees of any EPX group company (including Executive Directors), or any other person the Board deems eligible in its absolute discretion.
Award	<p>The Employee Incentive Plan provides flexibility for the Board to grant one or more of the following types of award:</p> <ul style="list-style-type: none"> - options to acquire shares (Incentive Options); - rights to acquire shares (Performance Right); - shares allocated under the Plan (Restricted Share); or - a right to a cash amount determined in reference to the value of shares (Incentive Right), (together Awards). Any shares issued under the Employee Incentive Plan will rank equally with other Shares issued by EP&T, except for any rights attaching to shares by reference to a record date prior to the date of their issue.
Maximum number of Awards that may be issued under the Employee Incentive Plan	21,400,000 Securities
Conditions	<p>The Board must set out the terms and conditions of the Award in the Invitation. The Invitation must include:</p> <ul style="list-style-type: none"> - the type(s) and number of Award(s) being offered or the method by which the number will be calculated; - the amount payable for the grant of an Award or the method by which the amount payable is calculated; and - any vesting conditions, or other condition including any vesting periods. <p>An invitation for an Incentive Option or Performance Right must include:</p> <ul style="list-style-type: none"> - requirements for exercising the Incentive Option (including any exercise price or exercise period);

	<ul style="list-style-type: none"> - whether exercising the Incentive Option or vesting of the Performance Right will only be satisfied by an allocation of shares to the participant; and - the date or circumstances in which the Incentive Option or Performance <p>Right may lapse. An invitation for an Incentive Right must include:</p> <ul style="list-style-type: none"> - how the amount of the Incentive Right is calculated; and - when the Incentive right will be paid.
<p>Rights to participate in new issues of securities</p>	<p>Incentive Options and Performance Rights do not confer on participants a right to participate in the new issue of securities to existing shareholders unless:</p> <ul style="list-style-type: none"> - the Incentive Option is entitled to be exercised, or the Performance Right has vested; - Shares have been allocated under the Employee Incentive Plan in respect of that Incentive Option or Performance Right before the determination of entitlements to new securities; or - the participant participates as a holder of allocated Shares.
<p>Issue price</p>	<p>Awards are to be issued at no cost to a participant unless the Invitation specifies otherwise, or in respect of any allocation of Restricted Shares which may be deducted from that employee’s remuneration (provided that arrangement is noted in the Invitation).</p> <p>The Board may approve a loan made by an EPX group company to a participant to satisfy any amount payable for the grant of Restricted Shares. If approved, the invitation to participate must specify the terms and conditions of that loan (including any repayment and dealing restrictions).</p>
<p>Trust arrangement</p>	<p>The Board may, in its discretion, determine that Restricted Shares will be held by a Trustee on behalf of the participant on the terms of the Trust Deed, and any other terms the Board determines. If Restricted Shares are to be held on trust, the invitation must set out:</p> <ul style="list-style-type: none"> - the name of the trust and trustee; - the participant’s right to exercise any voting right attached to those shares; and - the circumstances the participant can direct the trustee to transfer the Restricted Share into the participant’s name or sell the Restricted Share and pay any proceeds to the participant.

Annexure B: Nomination Letter for BDO AUDIT PTY LTD

(Attached to this Notice of Meeting)

For personal use only

Nomination of BDO Audit Pty Ltd as auditors

The Directors
EP&T Global Limited
Level 8, 210 George Street
SYDNEY NSW 2000

16 April 2025

Dear Directors

The undersigned being a member of EP&T Global Limited hereby nominates BDO Audit Pty Ltd for appointment as auditor of the company at the forthcoming annual general meeting.

Yours faithfully

Patrick Harsas

Patrick Harsas
CFO & shareholder of EP&T Global Limited



All Correspondence to:

- ✉ **By Mail** Boardroom Pty Limited
GPO Box 3993
Sydney NSW 2001 Australia
- 📠 **By Fax:** +61 2 9290 9655
- 💻 **Online:** www.boardroomlimited.com.au
- ☎ **By Phone:** (within Australia) 1300 737 760
(outside Australia) +61 2 9290 9600

YOUR VOTE IS IMPORTANT

For your vote to be effective it must be recorded **before 4.00pm (AEDT) on Tuesday, 25 November 2025.**

🖥 TO APPOINT A PROXY ONLINE

- STEP 1: VISIT** <https://www.votingonline.com.au/epxagm2025>
- STEP 2: Enter your Postcode OR Country of Residence (if outside Australia)**
- STEP 3: Enter your Voting Access Code (VAC):**

📱 BY SMARTPHONE



Scan QR Code using smartphone
QR Reader App

TO VOTE BY COMPLETING THE PROXY FORM

STEP 1 APPOINTMENT OF PROXY

Indicate who you want to appoint as your Proxy.

If you wish to appoint the Chair of the Meeting as your proxy, mark the box. If you wish to appoint someone other than the Chair of the Meeting as your proxy please write the full name of that individual or body corporate. If you leave this section blank, or your named proxy does not attend the meeting, the Chair of the Meeting will be your proxy. A proxy need not be a securityholder of the company. Do not write the name of the issuer company or the registered securityholder in the space.

Appointment of a Second Proxy

You are entitled to appoint up to two proxies to attend the meeting and vote. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by contacting the company's securities registry or you may copy this form.

To appoint a second proxy you must:

- (a) complete two Proxy Forms. On each Proxy Form state the percentage of your voting rights or the number of securities applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded.
- (b) return both forms together in the same envelope.

STEP 2 VOTING DIRECTIONS TO YOUR PROXY

To direct your proxy how to vote, mark one of the boxes opposite each item of business. All your securities will be voted in accordance with such a direction unless you indicate only a portion of securities are to be voted on any item by inserting the percentage or number that you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on a given item, your proxy may vote as he or she chooses. If you mark more than one box on an item for all your securities your vote on that item will be invalid.

Proxy which is a Body Corporate

Where a body corporate is appointed as your proxy, the representative of that body corporate attending the meeting must have provided an "Appointment of Corporate Representative" prior to admission. An Appointment of Corporate Representative form can be obtained from the company's securities registry.

STEP 3 SIGN THE FORM

The form **must** be signed as follows:

Individual: This form is to be signed by the securityholder.

Joint Holding: where the holding is in more than one name, all the securityholders should sign.

Power of Attorney: to sign under a Power of Attorney, you must have already lodged it with the registry. Alternatively, attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: this form must be signed by a Director jointly with either another Director or a Company Secretary. Where the company has a Sole Director who is also the Sole Company Secretary, this form should be signed by that person. **Please indicate the office held by signing in the appropriate place.**

STEP 4 LODGEMENT

Proxy forms (and any Power of Attorney under which it is signed) must be received no later than 48 hours before the commencement of the meeting, therefore by **4.00pm (AEDT) on Tuesday, 25 November 2025.** Any Proxy Form received after that time will not be valid for the scheduled meeting.

Proxy forms may be lodged using the enclosed Reply Paid Envelope or:

- 🖥 **Online** <https://www.votingonline.com.au/epxagm2025>
- 📠 **By Fax** + 61 2 9290 9655
- ✉ **By Mail** Boardroom Pty Limited
GPO Box 3993,
Sydney NSW 2001 Australia
- 👤 **In Person** Boardroom Pty Limited
Level 8, 210 George Street
Sydney NSW 2000 Australia

Attending the Meeting

If you wish to attend the meeting please bring this form with you to assist registration.

Your Address
This is your address as it appears on the company's share register. If this is incorrect, please mark the box with an "X" and make the correction in the space to the left. Securityholders sponsored by a broker should advise their broker of any changes.
Please note, you cannot change ownership of your securities using this form.

PROXY FORM

STEP 1 APPOINT A PROXY

I/We being a member/s of **EPX Limited** (Company) and entitled to attend and vote hereby appoint:

the **Chair of the Meeting (mark box)**

OR if you are **NOT** appointing the Chair of the Meeting as your proxy, please write the name of the person or body corporate (excluding the registered securityholder) you are appointing as your proxy below

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chair of the Meeting as my/our proxy at the Annual General Meeting of the Company to be held **virtually at <https://meetings.lumiconnect.com/300-343-048-230> on Thursday, 27 November 2025 at 4.00pm (AEDT)** and at any adjournment of that meeting, to act on my/our behalf and to vote in accordance with the following directions or if no directions have been given, as the proxy sees fit.

Chair of the Meeting authorised to exercise undirected proxies on remuneration related matters: If I/we have appointed the Chair of the Meeting as my/our proxy or the Chair of the Meeting becomes my/our proxy by default and I/we have not directed my/our proxy how to vote in respect of Resolutions (1,4 & 6), I/we expressly authorise the Chair of the Meeting to exercise my/our proxy in respect of these Resolutions even though Resolutions 1,4 & 6 are connected with the remuneration of a member of the key management personnel for the Company.

The Chair of the Meeting will vote all undirected proxies in favour of all Items of business (including Resolutions 1,4 & 6). If you wish to appoint the Chair of the Meeting as your proxy with a direction to vote against, or to abstain from voting on an item, you must provide a direction by marking the 'Against' or 'Abstain' box opposite that resolution.

STEP 2 VOTING DIRECTIONS
* If you mark the Abstain box for a particular item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your vote will not be counted in calculating the required majority if a poll is called.

		For	Against	Abstain*
Resolution 1	Adoption of Remuneration Report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 2	Re-election of Mr Paul Oneile as Director	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 3	Ratification of Placement Shares	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 4	Approval of Issue of Performance Rights to Directors and CEO	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 5	Appointment of Auditor (Special Resolution)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 6	Additional 10% Placement Capacity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 7	Consolidation of Capital of the Company	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

STEP 3 SIGNATURE OF SECURITYHOLDERS
This form must be signed to enable your directions to be implemented.

Individual or Securityholder 1	Securityholder 2	Securityholder 3
Sole Director and Sole Company Secretary	Director	Director / Company Secretary